This early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated May 15, 2026 11:53 UTC